B. C. Cho Et Al. , "Pembrolizumab plus epacadostat in patients with recurrent/metastatic head and neck squamous cell carcinoma (KEYNOTE-669/ECHO-304): a phase 3, randomized, open-label study," BMC CANCER , no.SUPPL 1, 2024
Cho, B. C. Et Al. 2024. Pembrolizumab plus epacadostat in patients with recurrent/metastatic head and neck squamous cell carcinoma (KEYNOTE-669/ECHO-304): a phase 3, randomized, open-label study. BMC CANCER , no.SUPPL 1 .
Cho, B. C., Brana, I., Cirauqui, B., AKSOY, S., Couture, F., Hong, R., ... Miller Jr, W. H.(2024). Pembrolizumab plus epacadostat in patients with recurrent/metastatic head and neck squamous cell carcinoma (KEYNOTE-669/ECHO-304): a phase 3, randomized, open-label study. BMC CANCER , no.SUPPL 1.
Cho, Byoung Et Al. "Pembrolizumab plus epacadostat in patients with recurrent/metastatic head and neck squamous cell carcinoma (KEYNOTE-669/ECHO-304): a phase 3, randomized, open-label study," BMC CANCER , no.SUPPL 1, 2024
Cho, Byoung C. Et Al. "Pembrolizumab plus epacadostat in patients with recurrent/metastatic head and neck squamous cell carcinoma (KEYNOTE-669/ECHO-304): a phase 3, randomized, open-label study." BMC CANCER , no.SUPPL 1, 2024
Cho, B. C. Et Al. (2024) . "Pembrolizumab plus epacadostat in patients with recurrent/metastatic head and neck squamous cell carcinoma (KEYNOTE-669/ECHO-304): a phase 3, randomized, open-label study." BMC CANCER , no.SUPPL 1.
@article{article, author={Byoung Chul Cho Et Al. }, title={Pembrolizumab plus epacadostat in patients with recurrent/metastatic head and neck squamous cell carcinoma (KEYNOTE-669/ECHO-304): a phase 3, randomized, open-label study}, journal={BMC CANCER}, year=2024}